Lipids in Psychiatric Disorders: Functional and Potential Diagnostic Role as Blood Biomarkers
Open accessThe DOI matches its Crossref record; 156 of the 157 references it cites were found in a registry or an index; 15 of the 127 sources its claims cite were checked for support.
Abstract
Lipids are a crucial component of the human brain, serving important structural and functional roles. They are involved in cell function, myelination of neuronal projections, neurotransmission, neural plasticity, energy metabolism, and neuroinflammation. Despite their significance, the role of lipids in the development of mental disorders has not been well understood. This review focused on the potential use of lipids as blood biomarkers for common mental illnesses, such as major depressive disorder, anxiety disorders, bipolar disorder, and schizophrenia. This review also discussed the impact of commonly used psychiatric medications, such as neuroleptics and antidepressants, on lipid metabolism. The obtained data suggested that lipid biomarkers could be useful for diagnosing psychiatric diseases, but further research is needed to better understand the associations between blood lipids and mental disorders and to identify specific biomarker combinations for each disease.
Overview
CoChat Summary
TL;DR
This narrative review summarizes evidence that blood lipid classes are altered across major depressive disorder, anxiety disorders, bipolar disorder, and schizophrenia, and that antipsychotics and antidepressants themselves affect lipid metabolism. It concludes that lipid biomarkers may aid diagnosis and prognosis, but associations remain incompletely understood and specific diagnostic combinations are not yet established.
Key findings
- Across reviewed studies, the most consistent schizophrenia findings were reductions in phosphatidylcholine (PC), phosphatidylethanolamine (PE), sphingomyelin (SM), and triacylglycerols (TGs); malondialdehyde was increased in all concerned studies, and HDL was decreased in two studies.
- In major depressive disorder, lysophosphatidylcholine (LPC) and lysophosphatidylethanolamine (LPE) were increased, while acylcarnitine (CAR), calcifediol, SM, and bile acids were mostly decreased; PC and malondialdehyde were mostly elevated.
- In anxiety disorders, almost all reviewed papers reported increased TGs, and polyunsaturated fatty acids (PUFAs) were mainly decreased; malondialdehyde was increased, while 20-oxo-22,23,24,25,26,27-hexanorvitamin D3 was decreased.
- One transdiagnostic study suggested 10 lipids could be used for diagnostics across psychiatric disorders; CAR and SM were decreased across all reviewed psychiatric disorders, and malondialdehyde was increased across all.
- Medication effects were prominent: typical and atypical antipsychotics increased cholesterol, TG, and LDL, with olanzapine and clozapine showing the worst side-effect profiles and aripiprazole, brexiprazole, cariprazine, lurasidone, and ziprasidone the most favorable; several studies found selective serotonin reuptake inhibitors increased TC, TGs, and LDL in depressed patients.
Methods
- Narrative review of blood lipid biomarkers in schizophrenia (SCZ), bipolar disorder (BPD), major depressive disorder (MDD), and anxiety disorders (AD), plus a section on antipsychotic and antidepressant effects on lipid metabolism.
- The authors summarized studies in Table S1 and Table 1, reporting over 29 SCZ studies, 19 MDD studies, 14 BPD studies, and 24 AD studies; only nine SCZ studies, four MDD studies, and six AD studies involved more than 100, 100, and 300 individuals, respectively.
- No new primary data or meta-analysis were reported; findings are synthesized from the cited literature, including broad lipidomic panels and specific lipid classes.
Limitations
- Stated: further research is needed to better understand associations between blood lipids and mental disorders and to identify specific biomarker combinations for each disease.
- Stated: most studies did not compare patients with diagnosed depression after treatment against a healthy control group, making it difficult to assess whether antidepressants affect lipid metabolism and restore normal lipid profiles.
- Evident from the text: many findings were inconsistent or multidirectional (e.g., PUFAs, Cers, TGs, cholesterol, and lipoproteins), several studies were small, and psychopharmacologic treatment is a major confounding factor for lipidome measurements.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
11 Valid · 4 Not valid · 84 Not checked · 30 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Elevated glucocorticoid levels increase phospholipase D activity [35].”
§ Lipids in Psychiatric Disorders: Functional and Potential Diagnostic Role as Blood Biomarkers > 2. Lipids and Their Role in Neuropsychiatric Disorders
What the sources say
- Supportedcites [35] Walther A. Cannistraci C.V. Simons K. Durán C. Gerl M.J. Wehrli S. Kirschbaum C. Lipidomics in Major Depressive Disorder Front. Psychiatry 2018 9 459 10.3389/fpsyt.2018.00459 30374314 PMC6196281 source
The Figure 2 legend ('The lipidome in MDD', p. ~7) states outright: 'Increased levels of glucocorticoids increase PLD activity.' The main text ('Lipidome associations with glucocorticoids and inflammatory markers', p. ~6) supports this with the in vitro finding that dexamethasone-treated M-1 cells express higher phospholipase D activity, hydrolyzing PC to PA. The claim reproduces the source's own general statement, so it is supported; the underlying experimental basis is a glucocorticoid (dexamethasone) cell-culture study (ref. 48, Kim et al., 2000), which this review reports and incorporates into its pathway model. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Nine studies evaluated the broad panels of different lipid markers in patients with SCZ [31,34,40,41,42,43,44,45,46] and detected statistical differences in the following lipid classes: fatty acyls, sterols, glycerolipids, sphingolipids, glycerophospholipids, and products of lipid metabolism.”
§ Lipids in Psychiatric Disorders: Functional and Potential Diagnostic Role as Blood Biomarkers > 2. Lipids and Their Role in Neuropsychiatric Disorders
What the sources say
- Not checked yetcites [31] Li M. Gao Y. Wang D. Hu X. Jiang J. Qing Y. Yang X. Cui G. Wang P. Zhang J. Impaired Membrane Lipid Homeostasis in Schizophrenia Schizophr. Bull. 2022 48 1125 1135 10.1093/schbul/sbac011 35751100 PMC9434453 source
- Supportedcites [34] Wang F. Guo L. Zhang T. Cui Z. Wang J. Zhang C. Xue F. Zhou C. Li B. Tan Q. Alterations in Plasma Lipidomic Profiles in Adult Patients with Schizophrenia and Major Depressive Disorder Medicina 2022 58 1509 10.3390/medicina58111509 36363466 PMC9697358 source
This citation identifies one of the nine studies, not a source for the count of nine or every lipid class listed across them. The Introduction describes a case-control study of adults with schizophrenia using plasma lipidomics, and Results §3.2 reports analysis of 30 lipid classes and 782 species, with statistically significant differences in several classes. (LLM, conf=0.92)
- Not checked yetcites [40] Liu Y. Song X. Liu X. Pu J. Gui S. Xu S. Tian L. Zhong X. Zhao L. Wang H. Alteration of Lipids and Amino Acids in Plasma Distinguish Schizophrenia Patients from Controls: A Targeted Metabolomics Study Psychiatry Clin. Neurosci. 2021 75 138 144 10.1111/pcn.13194 33421228 source
- Supportedcites [41] Tkachev A. Stekolshchikova E. Anikanov N. Zozulya S. Barkhatova A. Klyushnik T. Petrova D. Shorter Chain Triglycerides Are Negatively Associated with Symptom Improvement in Schizophrenia Biomolecules 2021 11 720 10.3390/biom11050720 34064997 PMC8151512 source
The Results (§3.1; page unavailable) report that this study assessed 322 plasma lipid species across 14 classes in patients with schizophrenia. Results (§3.2; page unavailable) report statistically significant changes in 22 lipids among patients with the least symptom improvement, including 20 triglycerides. The citing sentence attributes the full list of lipid classes to nine studies collectively, not to this study alone. (LLM, conf=0.88)
- Not checked yetcites [42] Yan L. Zhou J. Wang D. Si D. Liu Y. Zhong L. Yin Y. Unbiased Lipidomic Profiling Reveals Metabolomic Changes during the Onset and Antipsychotics Treatment of Schizophrenia Disease Metabolomics 2018 14 80 10.1007/s11306-018-1375-3 30830385 source
- Supportedcites [43] Orešič M. Seppänen-Laakso T. Sun D. Tang J. Therman S. Viehman R. Mustonen U. van Erp T.G. Hyötyläinen T. Thompson P. Phospholipids and Insulin Resistance in Psychosis: A Lipidomics Study of Twin Pairs Discordant for Schizophrenia Genome Med. 2012 4 1 10.1186/gm300 22257447 PMC3334549 source
The Results section (page unavailable) reports a broad lipidomics panel of 530 measured lipids in patients with schizophrenia and comparison groups. Table 2 reports a significant patient–co-twin difference for a triglyceride cluster (P = 0.039). This supports citing the paper as one of the studies in the group; the six lipid classes are presented as the studies’ collective findings, not as findings of this paper alone. (LLM, conf=0.87)
- Supportedcites [44] Costa A.C. Riça L.B. van de Bilt M. Zandonadi F.S. Gattaz W.F. Talib L.L. Sussulini A. Application of Lipidomics in Psychiatry: Plasma-Based Potential Biomarkers in Schizophrenia and Bipolar Disorder Metabolites 2023 13 600 10.3390/metabo13050600 37233641 PMC10222421 source
This paper is one of the studies cited in the nine-study list. Its Results (§3.1–3.2; page unavailable) report statistically significant features in the schizophrenia comparisons and differential lipids spanning fatty acids, sterols, glycerolipids, sphingolipids, and glycerophospholipids; §3.2 also examines lipid-metabolism pathways. It supports its inclusion as an example, rather than independently establishing the total of nine studies. (LLM, conf=0.88)
- Not checked yetcites [45] Wang D. Sun X. Maziade M. Mao W. Zhang C. Wang J. Cao B. Characterising Phospholipids and Free Fatty Acids in Patients with Schizophrenia: A Case-Control Study World J. Biol. Psychiatry 2021 22 161 174 10.1080/15622975.2020.1769188 32677491 source
- Not checked yetcites [46] Wang D. Cheng S.L. Fei Q. Gu H. Raftery D. Cao B. Sun X. Yan J. Zhang C. Wang J. Metabolic Profiling Identifies Phospholipids as Potential Serum Biomarkers for Schizophrenia Psychiatry Res. 2019 272 18 29 10.1016/j.psychres.2018.12.008 30579177 source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The levels of PC and PE did not differ significantly in FEP patients and medicated patients [53,54].”
§ Lipids in Psychiatric Disorders: Functional and Potential Diagnostic Role as Blood Biomarkers > 2. Lipids and Their Role in Neuropsychiatric Disorders
What the sources say
- Partly supportedcites [53] McEvoy J. Baillie R.A. Zhu H. Buckley P. Keshavan M.S. Nasrallah H.A. Dougherty G.G. Yao J.K. Kaddurah-Daouk R. Lipidomics Reveals Early Metabolic Changes in Subjects with Schizophrenia: Effects of Atypical Antipsychotics PLoS ONE 2013 8 e68717 10.1371/journal.pone.0068717 23894336 PMC3722141 sourceExperimental — accuracy not yet measured
The Results (Metabolic Signature of Disease; page unavailable) report that first-episode (FE) and recurrent-episode (RE) patients differed significantly in PE n3 concentrations, but not in the other PC and PE n3/n6 concentrations assessed. Thus, the blanket claim of no significant difference in both PC and PE is too broad. The comparison was between FE and RE groups at baseline, not explicitly between first-episode and currently medicated patients. (LLM, conf=0.87)
- Not checked yetcites [54] Kaddurah-Daouk R. McEvoy J. Baillie R. Zhu H.K. Yao J. Nimgaonkar V.L. Buckley P.F. Keshavan M.S. Georgiades A. Nasrallah H.A. Impaired Plasmalogens in Patients with Schizophrenia Psychiatry Res. 2012 198 347 352 10.1016/j.psychres.2012.02.019 22513041 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Increased saturated fatty acid-rich phospholipids, namely lysoPS (16:0), lysoPS (18:0), and SM (24:0), have been associated with inflammation and oxidative stress responses in depressed patients [35].”
§ Lipids in Psychiatric Disorders: Functional and Potential Diagnostic Role as Blood Biomarkers > 2. Lipids and Their Role in Neuropsychiatric Disorders
What the sources say
- Partly supportedcites [35] Walther A. Cannistraci C.V. Simons K. Durán C. Gerl M.J. Wehrli S. Kirschbaum C. Lipidomics in Major Depressive Disorder Front. Psychiatry 2018 9 459 10.3389/fpsyt.2018.00459 30374314 PMC6196281 sourceExperimental — accuracy not yet measured
The Human studies and The lipidome in MDD sections describe links between altered lipids and inflammation in depression, including phospholipids that release proinflammatory compounds. They do not report increased lysoPS (16:0), lysoPS (18:0), or SM (24:0), or associate those specific lipids with oxidative stress responses in depressed patients (pages unavailable in our copy). (LLM, conf=0.82)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Antipsychotic drugs produce metabolic side effects with a different extent depending on their type.”
§ Lipids in Psychiatric Disorders: Functional and Potential Diagnostic Role as Blood Biomarkers > 3. Effect of Medications on Lipid Metabolism > 3.1. Antipsychotics
What the sources say
- Supportedcites [131] Pillinger T. McCutcheon R.A. Vano L. Mizuno Y. Arumuham A. Hindley G. Beck K. Natesan S. Efthimiou O. Cipriani A. Comparative Effects of 18 Antipsychotics on Metabolic Function in Patients with Schizophrenia, Predictors of Metabolic Dysregulation, and Association with Psychopathology: A Systematic Review and Network Meta-Analysis Lancet Psychiatry 2020 7 64 77 10.1016/S2215-0366(19)30416-X 31860457 PMC7029416 source
The Discussion states that metabolic side-effects vary markedly between antipsychotics, identifying olanzapine and clozapine as having the worst profiles and several others as having the best. This directly supports the claim that the extent of metabolic side-effects depends on the drug. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
80 more claims · 6 with their cited sources checked
Create a free account to see all 129 claims and to verify the 112 references still open.
- Probably not a substantial claim. 7
- It may state two separate claims as one. 37
- The quote only partly states this claim. 3
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Lipids are integral to cellular processes, including neurotransmission, neuroplasticity, neural projection myelination, energy metabolism, and neuroinflammation (29).”
From Retrospective evaluation of novel serum inflammatory biomarkers in first-episode psychiatric disorders: diagnostic potential and immune dysregulation (2024) · doi:10.3389/fpsyt.2024.1442954 · cites this paper as [29]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Lipids in Psychiatric Disorders: Functional and Potential Diagnostic Role as Blood Biomarkers > 2. Lipids and Their Role in Neuropsychiatric Disorders
“Among the addressed studies, one was dedicated to the transdiagnostic lipid markers between four illnesses: MDD, BPD, AD, and SCZ [79].”
§ Lipids in Psychiatric Disorders: Functional and Potential Diagnostic Role as Blood Biomarkers > References
“79. Tao S. Zhang Y. Wang Q. Qiao C. Deng W. Liang S. Wei J. Wei W. Yu H. Li X. Identifying Transdiagnostic Biological Subtypes across Schizophrenia, Bipolar Disorder, and Major Depressive Disorder Based on Lipidomics Profiles”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Lipids in Psychiatric Disorders: Functional and Potential Diagnostic Role as Blood Biomarkers > 2. Lipids and Their Role in Neuropsychiatric Disorders
“Unidirectional changes were detected when studying the levels of 20-oxo-22,23,24,25,26,27-hexanorvitamin D3 and malondialdehyde.”
§ Lipids in Psychiatric Disorders: Functional and Potential Diagnostic Role as Blood Biomarkers > 2. Lipids and Their Role in Neuropsychiatric Disorders
“Thus, decreased levels of 20-oxo-22,23,24,25,26,26,27-hexanorvitamin D3 accompanied anxiety symptomatology [76,77].”
Citations
Cites
Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets
Wang, B., Wu, L., Chen, J., Dong, L., Chen, C., Wen, Z., Hu, J., Fleming, I., & Wang, D. W. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00443-w · Cited by 1,414
Pillinger, T., McCutcheon, R. A., Vano, L., Mizuno, Y., Arumuham, A., Hindley, G., Beck, K., Natesan, S., Efthimiou, O., Cipriani, A., et al. (2020) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30416-x · Cited by 1,090
Microglia in Neuroinflammation and Neurodegeneration: From Understanding to Therapy
Muzio, L., Viotti, A., & Martino, G. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.742065 · Cited by 581 · cited 1×
“Once abnormalities are detected, complex remodeling of the lipid composition of microglial cells occurs, providing inflammatory signaling and effector functions [26].”
BackgroundBrain lipidomics: From functional landscape to clinical significance
Yoon, J. H., Seo, Y., Jo, Y. S., Lee, S., Cho, E., Cazenave-Gassiot, A., Shin, Y.-S., Moon, M. H., An, H. J., Wenk, M. R., et al. (2022) · Science Advances · doi:10.1126/sciadv.adc9317 · Cited by 324
Metabolomic Mapping of Atypical Antipsychotic Effects in Schizophrenia
Kaddurah-Daouk, R., McEvoy, J., Baillie, R. A., Lee, D., Yao, J. K., Doraiswamy, P. M., & Krishnan, K. R. R. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002000 · Cited by 262 · cited 1×
“Among others, neuroleptic therapy affects lipid homeostasis [130,131].”
BackgroundMembrane Lipids in Presynaptic Function and Disease
Lauwers, E., Goodchild, R., & Verstreken, P. (2016) · Neuron · doi:10.1016/j.neuron.2016.02.033 · Cited by 229
Fatty Acids in Energy Metabolism of the Central Nervous System
Panov, A., Orynbayeva, Z., Vavilin, V., & Lyakhovich, V. (2014) · BioMed Research International · doi:10.1155/2014/472459 · Cited by 227
Liu, X., Zheng, P., Zhao, X., Zhang, Y., Hu, C., Li, J., Zhao, J., Zhou, J., Xie, P., & Xu, G. (2015) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5b00144 · Cited by 193
Membrane changes under oxidative stress: the impact of oxidized lipids
Itri, R., Junqueira, H. C., Mertins, O., & Baptista, M. S. (2014) · Biophysical Reviews · doi:10.1007/s12551-013-0128-9 · Cited by 191
Zhou, X., Liu, L., Lan, X., Cohen, D., Zhang, Y., Ravindran, A. V., Yuan, S., Zheng, P., Coghill, D., Yang, L., et al. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0047-z · Cited by 181
Lipid metabolism and storage in neuroglia: role in brain development and neurodegenerative diseases
Yang, D., Wang, X., Zhang, L., Fang, Y., Zheng, Q., Liu, X., Yu, W., Chen, S., Ying, J., & Hua, F. (2022) · Cell & Bioscience · doi:10.1186/s13578-022-00828-0 · Cited by 179
Mesa-Herrera, F., Taoro-González, L., Valdés-Baizabal, C., Diaz, M., & Marín, R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20153810 · Cited by 176
Lipids in Psychiatric Disorders and Preventive Medicine
Schneider, M., Levant, B., Reichel, M., Gulbins, E., Kornhuber, J., & Müller, C. P. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.06.002 · Cited by 175
Schizophrenia shows a unique metabolomics signature in plasma
He, Y., Yu, Z., Giegling, I., Xie, L., Hartmann, A. M., Prehn, C., Adamski, J., Kahn, R., Li, Y., Illig, T., et al. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.76 · Cited by 171
Orešič, M., Seppänen‐Laakso, T., Sun, D., Tang, J. P., Therman, S., Viehman, R., Mustonen, U., van Erp, T. G., Hyötyläinen, T., Thompson, P. M., et al. (2012) · eScholarship (California Digital Library) · Cited by 168
Demirkan, A., Isaacs, A., Ugocsai, P., Liebisch, G., Struchalin, M., Rudan, I., Wilson, J. F., Pramstaller, P. P., Gyllensten, U., Campbell, H., et al. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.11.001 · Cited by 163 · cited 6×
“↓ SPM 23:1 (anxiety symptoms) [63].”
BackgroundInfluentialMaes, M. H. J., Mihaylova, I., Kubera, M., Uytterhoeven, M., Vrydags, N., & Bosmans, E. (2009) · PubMed · Cited by 160
Plasma lipidomics reveals potential lipid markers of major depressive disorder
Liu, X., Li, J., Zheng, P., Zhao, X., Zhou, C., Hu, C., Hou, X., Wang, H., Xie, P., & Xu, G. (2016) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-016-9768-5 · Cited by 148
Mechanism of allosteric regulation of β2-adrenergic receptor by cholesterol
Manna, M., Niemelä, M., Tynkkynen, J., Javanainen, M., Kulig, W., Müller, D. J., Rog, T., & Vattulainen, I. (2016) · eLife · doi:10.7554/elife.18432 · Cited by 134
Healy-Stoffel, M., & Levant, B. (2018) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527317666180412153612 · Cited by 133 · cited 1×
“Several studies have suggested that omega-3 fatty acid deficiency can decrease dopamine levels, D2 receptor expression and mRNA, presynaptic dopamine vesicle amount, and increase dopamine cleavage [37].”
BackgroundTargeted lipidomics reveal derangement of ceramides in major depression and bipolar disorder
Brunkhorst-Kanaan, N., Klatt-Schreiner, K., Hackel, J., Schröter, K., Trautmann, S., Hahnefeld, L., Wicker, S., Reif, A., Thomas, D., Geisslinger, G., et al. (2019) · Metabolism · doi:10.1016/j.metabol.2019.04.002 · Cited by 131
Sphingolipid Organization in the Plasma Membrane and the Mechanisms That Influence It
Kraft, M. L. (2017) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2016.00154 · Cited by 131
LRP1 modulates the microglial immune response via regulation of JNK and NF‐ΚB signaling pathways
Yang, L., Liu, C.-C., Zheng, H., Kanekiyo, T., Atagi, Y., Jia, L., Wang, D., N’songo, A., Can, D., Xu, H., et al. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0772-7 · Cited by 129
Greasing the synaptic vesicle cycle by membrane lipids
Puchkov, D., & Haucke, V. (2013) · Trends in Cell Biology · doi:10.1016/j.tcb.2013.05.002 · Cited by 128
McEvoy, J., Baillie, R. A., Zhu, H., Buckley, P., Keshavan, M. S., Nasrallah, H. A., Dougherty, G. G., Yao, J. K., & Kaddurah-Daouk, R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068717 · Cited by 127 · cited 2×
“The levels of PC and PE did not differ significantly in FEP patients and medicated patients [53,54].”
BackgroundAssociation of Serum Vitamin D with Symptoms of Depression and Anxiety in Early Pregnancy
Huang, J. Y., Arnold, D., Qiu, C.-F., Miller, R. S., Williams, M. A., & Enquobahrie, D. A. (2014) · Journal of Women s Health · doi:10.1089/jwh.2013.4598 · Cited by 126 · cited 2×
“↓ anxiety symptoms [76,77].”
BackgroundSun, N., Zhang, J., Wang, J., Liu, Z., Wang, X., Kang, P., Yang, C., Liu, P., & Zhang, K. (2022) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13368 · Cited by 126
Assies, J., Pouwer, F., Lok, A., Mocking, R. J. T., Bockting, C. L. H., Visser, I., Abeling, N. G. G. M., Duran, M., & Schene, A. H. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010635 · Cited by 124
Omega-3 and omega-6 fatty acid levels in depressive and anxiety disorders
Thesing, C. S., Bot, M., Milaneschi, Y., Giltay, E. J., & Penninx, B. W. J. H. (2017) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2017.10.005 · Cited by 123
Atypical Antipsychotics Alter Cholesterol and Fatty Acid Metabolism in Vitro
Canfrán-Duque, A., Casado, M. E., Pastor, Ó., Sánchez-Wandelmer, J., de la Peña, G., Lerma, M., Mariscal, P., Bracher, F., Lasunción, M. A., & Busto, R. (2013) · Journal of Lipid Research · doi:10.1194/jlr.m026948 · Cited by 105 · cited 2×
“As cationic amphiphilic drugs, antipsychotics alkalinize lysosomes, affecting lysosomal function, as has been shown with haloperidol [134].”
BackgroundLipids as biomarkers of brain disorders
Hussain, G., Anwar, H., Rasul, A., Imran, A., Qasim, M., Zafar, S., Imran, M., Kamran, S. K. S., Aziz, N., Razzaq, A., et al. (2020) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2018.1529653 · Cited by 103
Brain lipid concentrations in bipolar disorder
Igarashi, M., Ma, K., Gao, F., Kim, H.-W., Greenstein, D., Rapoport, S. I., & Rao, J. S. (2010) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2009.08.001 · Cited by 101
Neuroinflammation: The Pathogenic Mechanism of Neurological Disorders
Gorji, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105744 · Cited by 101
Wei, Y., Wang, T., Li, G., Feng, J., Deng, L., Xu, H., Yin, L., Ma, J., Chen, D., & Chen, J. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.941728 · Cited by 99
Elevated Plasma Ceramides in Depression
Gracia-Garcia, P., Rao, V., Haughey, N. J., Ratnam Banduru, V. V., Smith, G., Rosenberg, P. B., Lobo, A., Lyketsos, C. G., & Mielke, M. M. (2011) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.23.2.215 · Cited by 95
MahmoudianDehkordi, S., Ahmed, A. T., Bhattacharyya, S., Han, X., Baillie, R. A., Arnold, M., Skime, M. K., John-Williams, L. S., Moseley, M. A., Thompson, J. W., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-020-01097-6 · Cited by 95 · cited 2×
“…citalopram and escitalopram administration revealed changes in several types of PC, namely alkyl-PC, lysopPC, and SM (e.g., increases in PC (36:2), PC (30:0), PC (34:3), PC-O (34:2), PC-O (36:3), LPC (24:0), and SM (24:0) and decreases in PC (36:4), PC (38:6), LPC (20:4), and SM (18:1)) [157–159].”
BackgroundA Perspective: Active Role of Lipids in Neurotransmitter Dynamics
Postila, P. A., & Róg, T. (2020) · Molecular Neurobiology · doi:10.1007/s12035-019-01775-7 · Cited by 93
Deisenhammer, E. A., Kramer-Reinstadler, K., Liensberger, D., Kemmler, G., Hinterhuber, H., & Wolfgang Fleischhacker, W. (2004) · Psychiatry Research · doi:10.1016/j.psychres.2003.09.007 · Cited by 92 · cited 1×
“Conversely, several studies did not reveal pronounced changes in lipid metabolism following treatment with antidepressants of different classes [150].”
Kopf, D., Westphal, S., Luley, C. W., Ritter, S., Gilles, M., Weber-Hamann, B., Lederbogen, F., Lehnert, H., Henn, F. A., Heuser, I., et al. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000138762.23482.63 · Cited by 92 · cited 1×
“Kopf et al. [146] have also demonstrated the increase in TG levels following their amitriptyline therapy.”
BackgroundIslam, M. R., Islam, M. R., Ahmed, I., Moktadir, A. A., Nahar, Z., Islam, M. S., Shahid, S. F. B., Islam, S. N., Islam, M. S., & Hasnat, A. (2018) · SAGE Open Medicine · doi:10.1177/2050312118773953 · Cited by 89
Impaired Plasmalogens in Patients with Schizophrenia
Kaddurah-Daouk, R., McEvoy, J., Baillie, R., Zhu, H., K. Yao, J., Nimgaonkar, V. L., Buckley, P. F., Keshavan, M. S., Georgiades, A., & Nasrallah, H. A. (2012) · Psychiatry Research · doi:10.1016/j.psychres.2012.02.019 · Cited by 89 · cited 2×
“The levels of PC and PE did not differ significantly in FEP patients and medicated patients [53,54].”
BackgroundMembrane lipids and transporter function
Stieger, B., Steiger, J., & Locher, K. P. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166079 · Cited by 88
A Potential Mechanism Underlying Atypical Antipsychotics-Induced Lipid Disturbances
Cai, H. L., Tan, Q. Y., Jiang, P., Dang, R. L., Xue, Y., Tang, M. M., Xu, P., Deng, Y., Li, H. D., & Yao, J. K. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.161 · Cited by 86 · cited 1×
“Moreover, additional treatment with mifepristone effectively reversed the lipid abnormalities induced by atypical antipsychotics [137].”
BackgroundBeyazyüz, M., Albayrak, Y., Eğilmez, O. B., Albayrak, N., & Beyazyüz, E. (2013) · Psychiatry Investigation · doi:10.4306/pi.2013.10.2.148 · Cited by 83 · cited 1×
“In Beyazyuz’s work, metabolic changes were only observed after the use of paroxetine, citalopram, and escitalopram, but not fluoxetine [148].”
BackgroundCao, B., Wang, D., Pan, Z., Brietzke, E., McIntyre, R. S., Musial, N., Mansur, R. B., Subramanieapillai, M., Zeng, J., Huang, N., et al. (2019) · Translational Psychiatry · doi:10.1038/s41398-018-0353-x · Cited by 81
Lipid profiles in schizophrenia associated with clinical traits: a five year follow-up study
Solberg, D. K., Bentsen, H., Refsum, H., & Andreassen, O. A. (2016) · BMC Psychiatry · doi:10.1186/s12888-016-1006-3 · Cited by 81
Sphingolipids in neuroinflammation: a potential target for diagnosis and therapy
Lee, J. Y., Jin, H. K., & Bae, J.-S. (2020) · BMB Reports · doi:10.5483/bmbrep.2020.53.1.278 · Cited by 80 · cited 1×
“SMs also participate in neuroinflammation through cytokine release, microglia activation, and other immune processes [29].”
BackgroundSerum fatty acid patterns in patients with schizophrenia: a targeted metabonomics study
Yang, X., Sun, L., Zhao, A., Hu, X., Qing, Y., Jiang, J., Yang, C., Xu, T., Wang, P., Liu, J., et al. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.152 · Cited by 78
The effect of antidepressants on lipid homeostasis: a cardiac safety concern?
McIntyre, R. S., Soczynska, J. K., Konarski, J. Z., & Kennedy, S. H. (2006) · Expert Opinion on Drug Safety · doi:10.1517/14740338.5.4.523 · Cited by 77
Lipidomics in Major Depressive Disorder
Walther, A., Cannistraci, C. V., Simons, K., Durán, C., Gerl, M. J., Wehrli, S., & Kirschbaum, C. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00459 · Cited by 77 · cited 7×
“Chronic stress has been thought to trigger two main pathways: the hypothalamic–pituitary–adrenal axis (HPA) and neuroinflammation [35].”
BackgroundInfluentialMahmoudianDehkordi, S., Bhattacharyya, S., Brydges, C. R., Jia, W., Fiehn, O., Rush, A. J., Dunlop, B. W., & Kaddurah-Daouk, R. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.937906 · Cited by 75
Metabolic Profiling Identifies Phospholipids as Potential Serum Biomarkers for Schizophrenia
Wang, D., Cheng, S. L., Fei, Q., Gu, H., Raftery, D., Cao, B., Sun, X., Yan, J., Zhang, C., & Wang, J. (2019) · Psychiatry Research · doi:10.1016/j.psychres.2018.12.008 · Cited by 73
Kuwano, N., Kato, T. A., Setoyama, D., Sato-Kasai, M., Shimokawa, N., Hayakawa, K., Ohgidani, M., Sagata, N., Kubo, H., Kishimoto, J., et al. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.01.014 · Cited by 69 · cited 4×
“Plasma tryptophan-kynurenine metabolites and CEs were significantly correlated in the MDD group, but not in the HC group [62].”
BackgroundInfluentialHuang, T., Wu, S., Chiang, Y.-S., & Chen, J. (2003) · Psychiatry Research · doi:10.1016/s0165-1781(03)00071-4 · Cited by 68
Prevalence of Vitamin D Deficiency in Adult Outpatients With Bipolar Disorder or Schizophrenia
Boerman, R., Cohen, D., Schulte, P. F. J., & Nugter, A. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000580 · Cited by 67
Sevincok, L., Buyukozturk, A., & Dereboy, F. (2001) · The Canadian Journal of Psychiatry · doi:10.1177/070674370104600110 · Cited by 65
Effect of Antipsychotic Medications on Glucose and Lipid Levels
Chaggar, P. S., Shaw, S. M., & Williams, S. G. (2011) · The Journal of Clinical Pharmacology · doi:10.1177/0091270010368678 · Cited by 65
Salivary cortisol, serum lipids, and adiposity in patients with depressive and anxiety disorders
Veen, G., Giltay, E. J., DeRijk, R. H., van Vliet, I. M., PELT, J. V., & Zitman, F. G. (2009) · Metabolism · doi:10.1016/j.metabol.2009.02.009 · Cited by 64
Impaired membrane lipid homeostasis in schizophrenia
Li, M., Gao, Y., Wang, D., Hu, X., Jiang, J., Qing, Y., Yang, X., Cui, G., Wang, P., Zhang, J., et al. (2022) · Schizophrenia Bulletin · doi:10.1093/schbul/sbac011 · Cited by 63
Pan, S.-J., Tan, Y.-L., Yao, S.-W., Xin, Y., Yang, X., Liu, J., & Xiong, J. (2018) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.207 · Cited by 63
Xing, Y., Tang, Y., Zhao, L., Wang, Q., Qin, W., Ji, X., Zhang, J., & Jia, J. (2016) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2016.09.028 · Cited by 63 · cited 2×
“In particular, Xing et al. demonstrated a positive association of Cer C 20:0 levels with anxiety symptoms in Parkinson’s disease [75].”
BackgroundSonawalla, S. B., Papakostas, G. I., Petersen, T. J., Yeung, A. S., Smith, M. M., Sickinger, A. H., Gordon, J., Israel, J. A., Tedlow, J. R., Lamon-Fava, S., et al. (2002) · Psychosomatics · doi:10.1176/appi.psy.43.4.310 · Cited by 62
SOBCZAK, S., HONIG, A., CHRISTOPHE, A., MAES, M., HELSDINGEN, R. W. C., DE VRIESE, S., & RIEDEL, W. J. (2004) · Psychological Medicine · doi:10.1017/s0033291703001090 · Cited by 61
Profiling of Lipidomics Before and After Antipsychotic Treatment in First-Episode Psychosis
Leppik, L., Parksepp, M., Janno, S., Koido, K., Haring, L., Vasar, E., & Zilmer, M. (2018) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-018-0971-6 · Cited by 61
Contribution of ceramides metabolism in psychiatric disorders
Bernal‐Vega, S., García‐Juárez, M., & Camacho‐Morales, A. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15759 · Cited by 61
De Berardis, D., Serroni, N., Campanella, D., Marini, S., Rapini, G., Valchera, A., Iasevoli, F., Mazza, M., Fornaro, M., Perna, G., et al. (2017) · Archives of Suicide Research · doi:10.1080/13811118.2015.1004485 · Cited by 61
Hummel, J., Westphal, S., Weber-Hamann, B., Gilles, M., Lederbogen, F., Angermeier, T., Luley, C., Deuschle, M., & Kopf, D. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05853blu · Cited by 60 · cited 1×
“In addition, Hummel et al. demonstrated that the improvement of patients’ symptoms after the antidepressant treatment was accompanied by an improvement in the LDL/HDL ratio [154].”
BackgroundDysfunctional plasmalogen dynamics in the plasma and platelets of patients with schizophrenia
Wood, P. L., Unfried, G., Whitehead, W. F., Phillipps, A., & Wood, J. A. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.11.032 · Cited by 59
Ong, W.-Y., Farooqui, T., & Farooqui, A. A. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710791859289 · Cited by 58
Hilgemann, D. W., Dai, G., Collins, A., Larricia, V., Magi, S., Deisl, C., & Fine, M. (2018) · Journal of General Physiology · doi:10.1085/jgp.201711875 · Cited by 58
The Effects of Mirtazapine on Plasma Lipid Profiles in Healthy Subjects
Nicholas, L. M., Ford, A. L., Esposito, S. M., Ekstrom, R. D., & Golden, R. N. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0805 · Cited by 54
Yao, J. K., Dougherty, G. G., Gautier, C. H., Haas, G. L., Condray, R., Kasckow, J., Kisslinger, B. L., Gurklis, J. A., & Messamore, E. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbv130 · Cited by 54
Adaptation of Lipid Profiling in Depression Disease and Treatment: A Critical Review
Pinto, B., Conde, T., Domingues, I., & Domingues, M. R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042032 · Cited by 51 · cited 1×
“This makes it difficult to assess the ability of antidepressants to affect lipid metabolism and restore normal lipid profiles [158].”
BackgroundRoles of palmitoylation in structural long-term synaptic plasticity
Ji, B., & Skup, M. (2021) · Molecular Brain · doi:10.1186/s13041-020-00717-y · Cited by 50
Haloperidol Disrupts Lipid Rafts and Impairs Insulin Signaling in SH-SY5Y Cells
Sánchez-Wandelmer, J., Dávalos, A., de la Peña, G., Cano, S., Giera, M., Canfrán-Duque, A., Bracher, F., Martín-Hidalgo, A., Fernández-Hernando, C., Lasunción, M. A., et al. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.01.051 · Cited by 49
Kim, E. Y., Lee, J. W., Lee, M. Y., Kim, S. H., Mok, H. J., Ha, K., Ahn, Y. M., & Kim, K. P. (2018) · Psychiatry Research · doi:10.1016/j.psychres.2018.04.029 · Cited by 49
Liu, Y., Song, X., Liu, X., Pu, J., Gui, S., Xu, S., Tian, L., Zhong, X., Zhao, L., Wang, H., et al. (2021) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13194 · Cited by 48
Profiling of Acylcarnitines in First Episode Psychosis before and after Antipsychotic Treatment
Kriisa, K., Leppik, L., Balõtšev, R., Ottas, A., Soomets, U., Koido, K., Volke, V., Innos, J., Haring, L., Vasar, E., et al. (2017) · Journal of Proteome Research · doi:10.1021/acs.jproteome.7b00279 · Cited by 47
A preliminary study of bipolar disorder type I by mass spectrometry-based serum lipidomics
Ribeiro, H. C., Klassen, A., Pedrini, M., Carvalho, M. S., Rizzo, L. B., Noto, M. N., Zeni‐Graiff, M., Sethi, S., Fonseca, F. A. H., Tasić, L., et al. (2017) · Psychiatry Research · doi:10.1016/j.psychres.2017.08.039 · Cited by 47
Beydoun, M. A., Beydoun, H. A., Dore, G. A., Fanelli-Kuczmarski, M. T., Evans, M. K., & Zonderman, A. B. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.4 · Cited by 45
Peter, H., Hand, I., Hohagen, F., Koenig, A., Mindermann, O., Oeder, F., & Wittich, M. (2002) · The Canadian Journal of Psychiatry · doi:10.1177/070674370204700608 · Cited by 44
Metabolic Effects of Antidepressant Treatment
Olguner Eker, O., Ozsoy, S., Eker, B., & Dogan, H. (2017) · Nöro Psikiyatri Arşivi · doi:10.5152/npa.2016.12373 · Cited by 44
S-Palmitoylation of Synaptic Proteins in Neuronal Plasticity in Normal and Pathological Brains
Buszka, A., Pytyś, A., Colvin, D., Włodarczyk, J., & Wójtowicz, T. (2023) · Cells · doi:10.3390/cells12030387 · Cited by 44
Jadoon, A., Chiu, C., McDermott, L., Cunningham, P., Frangou, S., Chang, C., Sun, I.-W., Liu, S., Lu, M., Su, K., et al. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.09.007 · Cited by 40
Álvarez-Mon, M. Á., Ortega, M. A., Montero, C. G., Fraile‐Μartinez, O., Lahera, G., Monserrat, J., Gomez-Lahoz, A. M., Molero, P., Gutiérrez-Rojas, L., Rodríguez–Jiménez, R., et al. (2022) · Journal of International Medical Research · doi:10.1177/03000605221094995 · Cited by 40
Alves, I., Staneva, G., Tessier, C., Salgado, G. F., & Nuss, P. (2011) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2011.02.021 · Cited by 40 · cited 2×
“Antipsychotics can alter membrane compartmentalization, which may differentially modulate the signaling cascade of the dopamine D2 receptor [138].”
BackgroundDong, M.-X., Hu, L., Wei, Y., & Chen, G. (2021) · Neuroscience Letters · doi:10.1016/j.neulet.2021.135626 · Cited by 40
de Almeida, V., Alexandrino, G. L., Aquino, A., Gomes, A. F., Murgu, M., Dobrowolny, H., Guest, P. C., Steiner, J., & Martins-de-Souza, D. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.109945 · Cited by 39 · cited 1×
“Almeida [141] investigated the lipidome changes in their blood plasma samples before and after 6 weeks of treatment with either risperidone, olanzapine, or quetiapine.”
BackgroundComparative effects of aripiprazole and selected antipsychotic drugs on lipid peroxidation in plasma
Dietrich‐Muszalska, A., & Kolińska‐Łukaszuk, J. (2018) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12631 · Cited by 38
Li, N., Yang, P., Tang, M., Liu, Y. H., Guo, W., Lang, B., Wang, J., Wu, H., Tang, H., Yu, Y. H., et al. (2022) · Schizophrenia · doi:10.1038/s41537-022-00214-2 · Cited by 38
Lipid and other plasma markers are associated with anxiety, depression, and fatigue.
Lieberman, H. R., Kellogg, M. D., Kramer, F. M., Bathalon, G. P., & Lesher, L. L. (2011) · Health Psychology · doi:10.1037/a0026499 · Cited by 37
Ceramide-Induced Alterations in Dopamine Transporter Function
Riddle, E. L., Rau, K. S., Topham, M. K., Hanson, G. R., & Fleckenstein, A. E. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)02727-9 · Cited by 37
Yan, L., Zhou, J., Wang, D., Si, D., Liu, Y., Zhong, L., & Yin, Y. (2018) · Metabolomics · doi:10.1007/s11306-018-1375-3 · Cited by 36 · cited 5×
“Cholesteryl esters ↑ in FEP [42].”
BackgroundInfluentialHsiao, C. (2006) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2006.03.008 · Cited by 34
Wang, J., Jiang, C., Chen, L., Song-ying, W., Lin, J., Gao, L., Xie, B., Dengzi, Z., Yang, R., Li, S., et al. (2016) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2016.05.005 · Cited by 34
Mocking, R. J. T., Nap, T. S., Westerink, A. M., Assies, J., Vaz, F. M., Koeter, M. W. J., Ruhé, H. G., & Schene, A. H. (2017) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2017.02.019 · Cited by 34
Plasma levels of n-3 fatty acids in bipolar patients: Deficit restricted to DHA
Pomponi, M., Janiri, L., Torre, G. L., Stasio, E. D., Nicola, M. D., Mazza, M., Martinotti, G., Bria, P., Lippa, S., Natili, R., et al. (2012) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.11.004 · Cited by 34
Zhuo, C., Hou, W., Tian, H., Wang, L., & Li, R. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-01080-1 · Cited by 34
Mongan, D., Healy, C., Jones, H. J., Zammit, S., Cannon, M. D., & Cotter, D. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01425-4 · Cited by 34
Saunders, E. F. H., Reider, A., Singh, G., Gelenberg, A. J., & Rapoport, S. I. (2015) · Bipolar Disorders · doi:10.1111/bdi.12337 · Cited by 33
Alterations in peripheral fatty acid composition in bipolar and unipolar depression
Scola, G., Versace, A., Metherel, A. H., Monsalve-Castro, L. A., Phillips, M. L., Bazinet, R. P., & Andreazza, A. C. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.12.025 · Cited by 32
State-dependent alterations of lipid profiles in patients with bipolar disorder
Huang, Y.-J., Tsai, S.-Y., Chung, K.-H., Chen, P.-H., Huang, S.-H., & Kuo, C.-J. (2018) · The International Journal of Psychiatry in Medicine · doi:10.1177/0091217417749786 · Cited by 32
Song, M., Liu, Y., Zhou, J., Shi, H., Su, X., Shao, M., Yang, Y., Wang, X., Zhao, J., Guo, D., et al. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115070 · Cited by 32
Aydemir, Ö., Çubukçuoğlu, Z., Erdin, S., Taş, C., Onur, E., & Berk, M. (2014) · Revista Brasileira de Psiquiatria · doi:10.1590/1516-4446-2013-1299 · Cited by 31
Mamalakis, G., Jansen, E. H. J. M., Cremers, H., Kiriakakis, M., Tsibinos, G., & Kafatos, A. (2006) · European Journal of Clinical Nutrition · doi:10.1038/sj.ejcn.1602413 · Cited by 30
Hurşıtoğlu, O., Orhan, F. Ö., Kurutaş, E. B., Doğaner, A., DURMUS, H. T., & KOPAR, H. (2021) · Nöro Psikiyatri Arşivi · doi:10.29399/npa.27372 · Cited by 30
Serum docosahexaenoic acid (DHA) is inversely associated with anxiety disorders in early pregnancy
Verly-Miguel, M., Farias, D. R., Pinto, T., Lepsch, J., Nardi, A. E., & Kac, G. (2014) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2014.12.002 · Cited by 29
Sphingolipid and Endocannabinoid Profiles in Adult Attention Deficit Hyperactivity Disorder
Brunkhorst-Kanaan, N., Trautmann, S., Schreiber, Y., Thomas, D., Kittel‐Schneider, S., Gurke, R., Geißlinger, G., Reif, A., & Tegeder, I. (2021) · Biomedicines · doi:10.3390/biomedicines9091173 · Cited by 29
Podbielska, M., Ariga, T., & Pokryszko‐Dragan, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105330 · Cited by 29
Cao, B., Wang, D., Pan, Z., McIntyre, R. S., Brietzke, E. M., Subramanieapillai, M., Nozari, Y., & Wang, J. (2019) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2019.1615639 · Cited by 28
Pillai, R. R., Wilson, A. B., Premkumar, N. R., Kattimani, S., Sagili, H., & Rajendiran, S. (2018) · PLoS ONE · doi:10.1371/journal.pone.0192811 · Cited by 28
McNamara, R. K., Jandacek, R., Tso, P., Blom, T. J., Welge, J. A., Strawn, J. R., Adler, C. M., DelBello, M. P., & Strakowski, S. M. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2015.09.035 · Cited by 27
Pistorio, E., Luca, M., Luca, A., Messina, V., & Calandra, C. (2011) · Lipids in Health and Disease · doi:10.1186/1476-511x-10-192 · Cited by 27
Changes in Plasma Cholesterol in Mood Disorder Patients: Does Treatment Make a Difference?
Gabriel, A. (2007) · Journal of Affective Disorders · doi:10.1016/j.jad.2006.08.015 · Cited by 26
Wang, D., Sun, X., Maziade, M., Mao, W., Zhang, C., Wang, J., & Cao, B. (2021) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2020.1769188 · Cited by 26
Alterations of Plasma Lipids in Adult Women With Major Depressive Disorder and Bipolar Depression
Zhang, T., Guo, L., Li, R., Wang, F., Yang, W., Yang, J.-B., Cui, Z.-Q., Zhou, C., Chen, Y., Yu, H., et al. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.927817 · Cited by 26
Stirton, H., Meek, B. P., Edel, A. L., Solati, Z., Surendran, A., Aukema, H. M., Modirrousta, M., & Ravandi, A. (2021) · PLoS ONE · doi:10.1371/journal.pone.0246592 · Cited by 26
Güneş, M., Camkurt, M. A., Bulut, M., Demir, S., İbiloğlu, A. O., Kaya, M., Atlı, A., Kaplan, İ., & Sır, A. (2016) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2016.14.4.345 · Cited by 26
Li, X., Yuan, X., Pang, L., Zhang, S., Li, Y., Huang, X., Fan, X., & Song, X. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.114582 · Cited by 26
Hu, M. X., Penninx, B. W. J. H., de Geus, E. J. C., Lamers, F., Kuan, D. C.-H., Wright, A. G. C., Marsland, A. L., Muldoon, M. F., Manuck, S. B., & Gianaros, P. J. (2018) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2018.06.013 · Cited by 25
Costa, A., Riça, L., van de Bilt, M., Zandonadi, F., Gattaz, W., Talib, L., & Sussulini, A. (2023) · Metabolites · doi:10.3390/metabo13050600 · Cited by 25
Köhnke, C., Herrmann, M., & Berger, K. (2020) · Nutritional Neuroscience · doi:10.1080/1028415x.2020.1843892 · Cited by 25
Blood-Based Oxidation Markers in Medicated and Unmedicated Schizophrenia Patients: A Meta-Analysis
Goh, X. X., Tang, P. Y., & Tee, S. F. (2022) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2021.102932 · Cited by 24 · cited 3×
“Both atypical and typical antipsychotics may worsen lipid peroxidation [49].”
BackgroundPlasma membrane and brain dysfunction of the old: Do we age from our membranes?
Martín, M. G., & Dotti, C. G. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1031007 · Cited by 24
Handbook of Neurochemistry and Molecular Neurobiology
Lajtha, Á., Gibson, G. E., & Dienel, G. A. (2007) · Springer eBooks · doi:10.1007/978-0-387-30411-3 · Cited by 24
Serum metabolomics study of anxiety disorder patients based on LC-MS
Kui, H., Su, H., Wang, Q., Liu, C., Li, Y., Tian, Y. L., Kong, J., Sun, G., & Huang, J. (2022) · Clinica Chimica Acta · doi:10.1016/j.cca.2022.06.022 · Cited by 23
Xiong, J., Yang, H., Wu, L., Shang, W. H., Shan, E., Liu, W., Hu, G., Xi, T., & Yang, J. (2014) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2014.07.019 · Cited by 23
Antipsychotic-Induced Increase in Lipid Biosynthesis: Activation through Inhibition?
Skrede, S., Steen, V. M., & Fern⊘, J. (2013) · Journal of Lipid Research · doi:10.1194/jlr.e034736 · Cited by 23 · cited 3×
“Antipsychotic drugs induce the inhibition of cholesterol biosynthesis, affecting the same enzymes with a different relative activity: ziprasidone > haloperidol > risperidone [129].”
BackgroundInfluentialHigh serum levels of malondialdehyde and antioxidant enzymes are associated with post-stroke anxiety
Liu, Z., Cai, Y., Zhang, X., Zhu, Z., & He, J. (2018) · Neurological Sciences · doi:10.1007/s10072-018-3287-4 · Cited by 22
Uddin, S., Sultana, F., Uddin, M. G., Dewan, S. M. R., Hossain, M. K., & Islam, M. S. (2021) · Health Science Reports · doi:10.1002/hsr2.291 · Cited by 22
Chen, L., Zhu, H., Harshfield, G. A., Treiber, F. A., Pollock, J. S., Pollock, D., Okereke, O. I., Su, S., & Dong, Y. (2020) · doi:10.20944/preprints202006.0008.v1 · Cited by 22 · cited 3×
“↓ anxiety symptoms [76,77].”
BackgroundCai, H., Cao, T., Li, N., Fang, P., Xu, P., Wu, X., Zhang, B., & Xiang, D. (2019) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-019-01956-2 · Cited by 19
Homorogan, C., Nitusca, D., Enatescu, V., Schubart, P., Moraru, C., Socaciu, C., & Marian, C. (2021) · Metabolites · doi:10.3390/metabo11070466 · Cited by 19 · cited 1×
“…citalopram and escitalopram administration revealed changes in several types of PC, namely alkyl-PC, lysopPC, and SM (e.g., increases in PC (36:2), PC (30:0), PC (34:3), PC-O (34:2), PC-O (36:3), LPC (24:0), and SM (24:0) and decreases in PC (36:4), PC (38:6), LPC (20:4), and SM (18:1)) [157–159].”
BackgroundSmesny, S., Langbein, K., Rzanny, R., Gussew, A., Burmeister, H. P., Reichenbach, J. R., & Sauer, H. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.02.031 · Cited by 18 · cited 1×
“…increased the level of adenosine triphosphate in the left dorsolateral prefrontal cortex, left anterior temporal cortex, left insular cortex, basal ganglia, and anterior cerebellum, and increased the levels of phosphomonoesters, phosphodiesters, and phosphocreatine in these brain regions [139].”
BackgroundDissipative dynamics of fluid lipid membranes enriched in cholesterol
Arriaga, L. R., Rodríguez-García, R., Moleiro, L. H., Prévost, S. F., López‐Montero, I., Hellweg, T., & Monroy, F. (2017) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2017.07.007 · Cited by 18
Wang, F., Guo, L., Zhang, T., Cui, Z., Wang, J., Zhang, C., Xue, F., Zhou, C., Li, B., Tan, Q., et al. (2022) · Medicina · doi:10.3390/medicina58111509 · Cited by 18
Nandeesha, H., Keshri, N., Rajappa, M., & Menon, V. (2023) · Archives of Physiology and Biochemistry · doi:10.1080/13813455.2020.1839500 · Cited by 17
From seconds to days: Neural plasticity viewed through a lipid lens
Vaughen, J. P., Theisen, E. K., & Clandinin, T. R. (2023) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2023.102702 · Cited by 17
Zhou, X., Long, T., Haas, G. L., Cai, H., & Yao, J. K. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00784 · Cited by 17
PCSK9 Mediates Dyslipidemia Induced by Olanzapine Treatment in Schizophrenia Patients
Huang, J., Xiao, J., Peng, Z., Shao, P., Sun, M., Long, Y., Wang, X., Shen, M., Kang, D., Yang, Y., et al. (2022) · Psychopharmacology · doi:10.1007/s00213-021-06042-z · Cited by 16 · cited 1×
“The negative effect of olanzapine on lipid homeostasis has been detected even in patients with a first episode of psychosis [132].”
BackgroundTao, S., Zhang, Y., Wang, Q., Qiao, C., Deng, W., Liang, S., Wei, J., Wei, W., Yu, H., Li, X., et al. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.969575 · Cited by 15
Noordam, R., Aarts, N., de Keyser, C. E., Albert Hofman, D., Stricker, B. H. C., & Visser, L. E. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115592340 · Cited by 15
Novel Phospholipid Signature of Depressive Symptoms in Patients with Coronary Artery Disease
Chan, P., Suridjan, I., Mohammad, D., Herrmann, N., Mazereeuw, G., Hillyer, L. M., Ma, D. W. L., Oh, P. I., & Lanctôt, K. L. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.008278 · Cited by 15
Frajerman, A., Chaumette, B., Farabos, D., Després, G., Simonard, C., Lamazière, A., Krebs, M., & Kébir, O. (2023) · Nutrients · doi:10.3390/nu15092215 · Cited by 15
Islam, M. R., Ahmed, M. U., Islam, M. S., Sayeed, M. S. B., Sadia, F. Z., Chowdhury, Z., Nahar, Z., & Hasnat, A. (2013) · Drug Research · doi:10.1055/s-0033-1358758 · Cited by 13
Casseb, G. A. S., Ambrósio, G., Rodrigues, A. L. S., & Kaster, M. P. (2019) · Metabolic Brain Disease · doi:10.1007/s11011-018-0371-7 · Cited by 13
Department of Psychiatry, D. U. M. F., Uyar, B., Budak, E. A., & Department of Psychiatry, D. U. M. F. (2022) · PSYCHIATRIA DANUBINA · doi:10.24869/psyd.2022.687 · Cited by 12 · cited 1×
“↑ LDL [34], ↓ HDL [125], ↓ HDL-c postpartum [57], and ↓ HDL-C [62].”
Plasma sterols and depressive symptom severity in a population-based cohort
Cenik, B., Cenik, C., Snyder, M. P., & Brown, E. S. (2017) · PLoS ONE · doi:10.1371/journal.pone.0184382 · Cited by 12
Canfrán-Duque, A., Pastor, Ó., García-Seisdedos, D., Molina, Y. L., Babiy, B., Lerma, M., Sánchez-Castellano, C., Martínez-Botas, J., Gómez-Coronado, D., Lasunción, M. A., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22083919 · Cited by 11
Plasma oxysterols in drug-free patients with schizophrenia
Guidara, W., Messedi, M., Naifar, M., Maalej, M., Khrouf, W., Grayaa, S., Maalej, M., Bonnefont-Rousselot, D., Lamari, F., & Ayadi, F. (2022) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2022.106123 · Cited by 11
Shorter Chain Triglycerides Are Negatively Associated with Symptom Improvement in Schizophrenia
Tkachev, A., Stekolshchikova, E., Anikanov, N., Zozulya, S., Barkhatova, A., Klyushnik, T., & Petrova, D. (2021) · Biomolecules · doi:10.3390/biom11050720 · Cited by 11 · cited 2×
“For example, such correlations have been detected for shorter-chain TGs [41] and oxysterols [55].”
BackgroundCholesterol levels in panic disorder, generalized anxiety disorder and major depression
Lacerda, A. L. T., Caetano, D., & Caetano, S. C. (2000) · Arquivos de Neuro-Psiquiatria · doi:10.1590/s0004-282x2000000300002 · Cited by 10
Ceramides: Shared Lipid Biomarkers of Cardiovascular Disease and Schizophrenia
Tkachev, A., Stekolshchikova, E., Morozova, A. Y., Anikanov, N. A., Zorkina, Y., Alekseyeva, P. N., Khobta, E. B., Andreyuk, D., Zozulya, S. A., Barkhatova, A., et al. (2021) · Consortium Psychiatricum · doi:10.17816/cp101 · Cited by 10
Self-citationZhang, G., Ye, X., Wang, X., Lin, Y., Zhu, C., Pan, J., Yin, X., Ye, M., Lv, W., Tang, W., et al. (2023) · Schizophrenia Research · doi:10.1016/j.schres.2023.03.046 · Cited by 9 · cited 1×
“TC levels were positively associated with the Repeated Battery for the Assessment of Neuropsychological Status (RBANS) subscale scores of immediate memory and language [56].”
MethodPlasma metabolites in first episode psychoses
Costa, A. C., Joaquim, H. P. G., Talib, L. L., Serpa, M. H., Zanetti, M. V., & Gattaz, W. F. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.11.010 · Cited by 7
Correlation of Selective Serotonin Re-Uptake Inhibitor Use with Weight Gain and Metabolic Parameters
Yosmaoglu, A., Fistikci, N., Keyvan, A., Hacioglu, M., Erten, E., Saatcioglu, O., & Kora, K. (2013) · Anatolian Journal of Psychiatry · doi:10.5455/apd.36693 · Cited by 5
Orešič, M., Seppänen-Laakso, T., Sun, D., Tang, J., Therman, S., Viehman, R., Mustonen, U., van Erp, T. G., Hyötyläinen, T., Thompson, P., et al. (2012) · Genome Medicine · doi:10.1186/gm300 · Cited by 5 · cited 2×
“↑ LPC [40], ↑ LPC 18:1 [44], ↓ [34,43,46] ↓ in FEP [42], mostly ↓ membrane LPC [31] ↑ 4 ↓ 19 [45] ↑ [58,59] ↑ LysoPC (16:0) and LysoPC (18:0) [111], and ↑ LPC [106], ↑ LPC [106].”
Cited by
(2024) · doi:10.3389/fpsyt.2024.1442954 · Cited by 15
Wang, Y., Chen, H., Wang, J., Chen, S., Liu, J., Chen, X., Li, S., Tang, H., Zhou, J., Ye, Y., et al. (2025) · Depression and Anxiety · doi:10.1155/da/5564796 · Cited by 15
Neural Spectral Prediction for Structure Elucidation with Tandem Mass SpectrometryPreprint
Wang, R., Manjrekar, M., Mahjour, B. A., Ávila-Pacheco, J., Provenzano, J., Reynolds, E. E., Lederbauer, M., Mashin, E., Goldman, S., Wang, M., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.28.656653 · Cited by 19
Bisle, E., Haange, S., Rojas, R., Behnke, A., Karabatsiakis, A., Gumpp, A. M., Mack, M., Mavioğlu, R. N., Lutz‐Bonengel, S., Rolle-Kampczyk, U. E., et al. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116569 · Cited by 10
Ungur, A. P., Socaciu, A. I., Bârsan, M., Râjnoveanu, A. G., Ionuţ, R., Socaciu, C., & Procopciuc, L. M. (2025) · Clocks & Sleep · doi:10.3390/clockssleep7030036 · Cited by 6
Metadata
- Authors
- Zorkina, Y., Ushakova, V., Ochneva, A., Tsurina, A., Abramova, O., Savenkova, V., Goncharova, A., Alekseenko, I., Morozova, I., Riabinina, D., Kostyuk, G., & Morozova, A.
- Affiliations
- Federal Medical Research Centre for Psychiatry and Narcology (RU)
- Mental-Health Clinic No. 1 Named after N.A. Alekseev, Zagorodnoe Highway 2, 115191 Moscow, Russia
- Moscow Center for Healthcare Innovations, 123473 Moscow, Russia
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academi of Science, 142290 Moscow, Russia
- Corresponding author
- Zorkina, Yana
- ORCID
- Venue
- Metabolites
- Publisher
- MDPI AG
- Published
- 2024-01-23
- Volume
- 14
- Issue
- 2
- Pages
- 80
- ISSN
- 2218-1989 (ISSN-L)
- PMC
- PMC10890164
- OpenAlex
- W4391131005
- Semantic Scholar
- e228f4240ba3c715551466152dfa01310093988b
- Cited by
- 36
- References
- 157
- Citations by year
- 2026: 13 · 2025: 19 · 2024: 4
- FWCI
- 1.47
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Metabolites (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Moscow Center for Innovative Technologies in Healthcare (2707-2/22)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolomics and Mass Spectrometry Studies
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- serum lipids, lipid biomarkers, mental illness, major depressive disorder, anxiety disorders, bipolar disorder, schizophrenia, lipid metabolism, antipsychotic drugs, antidepressants, neuroinflammation, psychiatric diagnosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

